Albiglutide

Mechanism (as reported)

Research on GLP-1 receptor agonists reports shared actions including augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying to prevent large post-meal glycemic increments, and reduction in calorie intake and body weight; long-acting agents (including albiglutide) are reported to have stronger effects on fasting plasma glucose and HbA1c, with effects on gastric emptying decreasing over time (tachyphylaxis). (PMIDs: 33068776) Additional sources describe GLP-1 receptor agonists as prolonging GLP-1 activity and report that short-acting agents primarily lower postprandial glucose via inhibition of gastric emptying, while long-acting agents have a stronger effect on fasting glucose mediated predominantly through insulinotropic and glucagonostatic actions. (PMIDs: 22945360) A review specific to albiglutide reports it augments glucose-dependent insulin secretion and slows gastric emptying. (PMIDs: 26092960)

Key findings (each cites a source)

• A review reported that GLP-1 receptor agonists are administered as injections on schedules ranging from twice daily to once weekly, including once-weekly agents such as albiglutide. (PMIDs: 33068776) [PMID 33068776]
• A review reported that GLP-1 receptor agonists share mechanisms including augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and reduction in calorie intake and body weight; it also reported that long-acting agents (including albiglutide) have more profound effects on overnight and fasting plasma glucose and HbA1c, and that gastric emptying effects decrease over time. (PMIDs: 33068776) [PMID 33068776]
• A review described GLP-1 as being degraded within ~2–3 minutes in circulation and stated that various GLP-1 receptor agonists were developed to provide prolonged in vivo actions; it categorized agents as short-acting (e.g., exenatide, lixisenatide) versus long-acting (including albiglutide) and linked pharmacokinetic differences to pharmacodynamic profiles (postprandial versus fasting glucose effects). (PMIDs: 22945360) [PMID 22945360]